Patents by Inventor Murielle Veniant-Ellison
Murielle Veniant-Ellison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180311372Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.Type: ApplicationFiled: January 16, 2018Publication date: November 1, 2018Applicant: AMGEN INC.Inventors: Yuan CHENG, Chawita NETIROJJANAKUL, Jerry Ryan HOLDER, Bin WU, James R. FALSEY, Bradley J. HERBERICH, Kelvin SHAM, Leslie P. MIRANDA, Shu-Chen LU, Murielle VENIANT-ELLISON, Shanaka STANISLAUS, Junming YIE, Jing XU
-
Publication number: 20180280474Abstract: The invention relates method of treating a patient in need thereof with a long acting agonist to the FGF21 signaling pathway. In a particular embodiment, the invention relates to the use of molecules that stimulate the FGF21 signaling pathway, such as long acting FGF21 polypeptides or agonist antibodies, to treat disorders or diseases associated with excess bile acid. The invention further relates to pharmaceutical formulations and dosing of long acting agonists of the FGF21 signaling pathway suitable for treating bile acid related disorders.Type: ApplicationFiled: September 30, 2016Publication date: October 4, 2018Inventors: Jing Xu, Shanaka Stanislaus, Mei-Hsiu M. Chen, Clarence H. Hale, Murielle Veniant-Ellison
-
Patent number: 9862752Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.Type: GrantFiled: July 31, 2014Date of Patent: January 9, 2018Assignee: Amgen Inc.Inventors: Yumei Xiong, Yi Zhang, Jackie Z. Sheng, Agnes Eva Hamburger, Murielle Veniant-Ellison, Grant Shimamoto, Xiaoshan Min, Zhulun Wang, Jie Tang, Gunasekaran Kannan, Marissa Mock, Kenneth Walker
-
Patent number: 9714276Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.Type: GrantFiled: January 28, 2013Date of Patent: July 25, 2017Assignee: Amgen Inc.Inventors: Yumei Xiong, Yi Zhang, Jackie Zeqi Sheng, Agnes Eva Hamburger, Murielle Veniant-Ellison, Grant Shimamoto, Xiaoshan Min, Zhulun Wang, Jie Tang, Gunasekaran Kannan, Kenneth W. Walker, Bryan Lemon
-
Publication number: 20160168213Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.Type: ApplicationFiled: July 31, 2014Publication date: June 16, 2016Inventors: Yumei XIONG, Yi ZHANG, Jackie Z. SHENG, Agnes Eva HAMBURGER, Murielle VENIANT-ELLISON, Grant SHIMAMOTO, Xiaoshan MIN, Zhulun WANG, Jie TANG, Gunasekaran KANNAN, Marissa MOCK, Kenneth WALKER
-
Publication number: 20140378665Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.Type: ApplicationFiled: January 28, 2013Publication date: December 25, 2014Inventors: Yumei Xiong, Yi Zhang, Jackie Zeqi Sheng, Agnes Eva Hamburger, Murielle Veniant-Ellison, Grant Shimamoto, Xiaoshan Min, Zhulun Wang, Jie Tang, Gunasekaran Kannan, Kenneth W. Walker, Bryan Lemon
-
Publication number: 20130203659Abstract: GLP-1 compounds comprising GLP-1 analogs and methods of using the GLP-1 compounds for treating metabolic disorders, enhancing insulin expression, and promoting insulin secretion in a patient are provided.Type: ApplicationFiled: October 15, 2012Publication date: August 8, 2013Inventors: Leslie P. MIRANDA, Katherine Ann WINTERS, Murielle VENIANT-ELLISON
-
Publication number: 20130030036Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.Type: ApplicationFiled: June 22, 2012Publication date: January 31, 2013Inventors: Kenneth W. Dobie, Sanjay Bhanot, Murielle Veniant-Ellison, Richard A. Lindberg, John R. Shutter, Robert McKay, Sanjay K. Pandey
-
Patent number: 8288339Abstract: GLP-1 compounds comprising GLP-1 analogs and methods of using the GLP-1 compounds for treating metabolic disorders, enhancing insulin expression, and promoting insulin secretion in a patient are provided.Type: GrantFiled: April 20, 2007Date of Patent: October 16, 2012Assignee: Amgen Inc.Inventors: Colin Victor Gegg, Jr., Leslie Phillip Miranda, Katherine Ann Winters, Murielle Veniant-Ellison
-
Patent number: 7807649Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.Type: GrantFiled: April 23, 2007Date of Patent: October 5, 2010Assignee: Isis Pharmaceuticals, Inc.Inventors: Kenneth W. Dobie, Sanjay Bhanot, Murielle Veniant-Ellison, Richard A. Lindberg, John R. Shutter, Robert McKay, Sanjay K. Pandey
-
Publication number: 20100048468Abstract: GLP-1 compounds comprising GLP-1 analogs and methods of using the GLP-1 compounds for treating metabolic disorders, enhancing insulin expression, and promoting insulin secretion in a patient are provided.Type: ApplicationFiled: April 20, 2007Publication date: February 25, 2010Applicant: AMGEN INC.Inventors: Colin Victor Gegg, JR., Leslie Phillip Miranda, Katherine Ann Winters, Murielle Veniant-Ellison
-
Publication number: 20080153767Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.Type: ApplicationFiled: April 23, 2007Publication date: June 26, 2008Inventors: Kenneth W. Dobie, Sanjay Bhanot, Murielle Veniant-Ellison, Richard A. Lindberg, John R. Shutter, Robert McKay, Sanjay K. Pandey
-
Patent number: 7229976Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.Type: GrantFiled: September 25, 2003Date of Patent: June 12, 2007Assignee: Isis Pharmaceuticals, Inc.Inventors: Kenneth W. Dobie, Sanjay Bhanot, Murielle Veniant-Ellison, Richard A. Lindberg, John R. Shutter
-
Publication number: 20060275285Abstract: The invention provides methods of identifying modulators, for example, inhibitors, of a G-protein coupled receptor. The modulators can be used for the treatment or prevention of metabolic disorders such as dyslipidemia, metabolic syndrome and obesity. The invention also provides methods of treating or preventing metabolic disorders by administering modulators of G-protein coupled receptor function.Type: ApplicationFiled: April 27, 2006Publication date: December 7, 2006Applicant: Amgen Inc.Inventors: Wei Gu, Melissa Graham, Murielle Veniant-Ellison
-
Publication number: 20040097459Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.Type: ApplicationFiled: September 25, 2003Publication date: May 20, 2004Inventors: Kenneth W. Dobie, Sanjay Bhanot, Murielle Veniant-Ellison, Richard A. Lindberg, John R. Shutter